Researchers from Adarx Pharmaceuticals Inc. presented preclinical and early clinical data on agazisiran (ADX-038), a double-stranded, GalNAc-conjugated siRNA developed to reduce complement factor B (CFB) expression.
Source disclosure
This is a source-linked briefing. Read the original report from Bioworld .